research use only
Cat.No.S3050
| Related Targets | Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other 5-HT Receptor Inhibitors | WAY-100635 Maleate Puerarin Serotonin (5-HT) HCl SB269970 HCl Ketanserin BRL-15572 Dihydrochloride Nuciferine RS-127445 Flopropione Azacyclonol |
|
In vitro |
Water : 67 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 332.87 | Formula | C19H24N2O.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 135729-62-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | RS 25259, RS 25259 197 | Smiles | C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5.Cl | ||
| Targets/IC50/Ki |
5-HT3
|
|---|---|
| In vitro |
Palonosetron is a highly potent, selective, second-generation 5-HT3 receptor antagonist with a 5-HT3 receptor binding affinity that is ∼100-fold higher than other 5-HT3 receptor antagonists (pKi 10.5 compared with 8.91 for granisetron, 8.81 for tropisetron, 8.39 for ondansetron, 7.6 for dolasetron). Palonosetron also has an extended plasma elimination half-life of ∼40 h, significantly longer than others in its class (ondansetron, 4 h; tropisetron, 7.3 h; dolasetron, 7.5 h; ranisetron, 8.9 h).
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04486157 | Completed | Healthy |
HK inno.N Corporation |
March 18 2021 | Phase 1 |
| NCT04466046 | Completed | Postoperative Nausea and Vomiting |
Daegu Catholic University Medical Center |
September 4 2019 | -- |
| NCT03148704 | Unknown status | Palonosetron |
Cttq |
March 8 2017 | -- |
| NCT00982995 | Terminated | Nausea|Vomiting|Terminally Ill |
University of Michigan Rogel Cancer Center |
November 2010 | Phase 2 |
| NCT01074697 | Completed | Nausea|Vomiting|Genital Neoplasms Female |
Odense University Hospital|Helsinn Healthcare SA |
April 2010 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.